AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS
The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing severe illness. Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or another non-clinic location if available. The total study duration is up to 24 weeks.
Inclusion Criteria:
Exclusion Criteria:
Newport News, Virginia 23606, United States
San Miguel de Tucumán, Tucumán Province 4000, Argentina
Haskovo, 6300, Bulgaria
Rousse, 7002, Bulgaria
Sliven, 8800, Bulgaria
Stara Zagora, 6000, Bulgaria
Tsarevo, 8260, Bulgaria
Vratsa, 3000, Bulgaria
Pavan PURI Bikaner, Rajasthan, 334003, India
Monterrey, Nuevo León 64060, Mexico
Nam-gu, 61748, South Korea
Pathum Wan District,, Bangkok 10330, Thailand
Pathumwan,, Bangkok 10330, Thailand
Pathumwan, Bangkok 10330, Thailand
Muang, Changwat Khon Kaen 40002, Thailand
Hat Yai, Changwat Songkhla 90110, Thailand
Beykoz / Istanbul, 34810, Turkey (Türkiye)
Istanbul, 34020, Turkey (Türkiye)
Istanbul, 34452, Turkey (Türkiye)
Konak/Izmir, 35170, Turkey (Türkiye)
Dnipro, 49069, Ukraine
Ivano-Frankivsk, 76007, Ukraine
Ivano-Frankivsk, 76018, Ukraine
Kharkiv, 61002, Ukraine
Kharkiv, 61096, Ukraine
Kyiv, 01601, Ukraine
Kyiv, 02091, Ukraine
Kyiv, 03049, Ukraine
Kyiv, 04050, Ukraine
Lviv, 79008, Ukraine
Poltava, 36011, Ukraine
Tarasove Village, 45625, Ukraine